Compare LDOS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LDOS | RPRX |
|---|---|---|
| Founded | 1969 | 1996 |
| Country | United States | United States |
| Employees | 47000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 19.5B |
| IPO Year | 2005 | 2020 |
| Metric | LDOS | RPRX |
|---|---|---|
| Price | $158.54 | $48.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $207.77 | $50.00 |
| AVG Volume (30 Days) | 789.4K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | 1.10% | ★ 1.93% |
| EPS Growth | ★ 20.82 | N/A |
| EPS | ★ 11.14 | 1.78 |
| Revenue | ★ $17,174,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $5.59 | $38.30 |
| Revenue Next Year | $4.06 | $4.80 |
| P/E Ratio | ★ $14.03 | $27.41 |
| Revenue Growth | 3.07 | ★ 5.06 |
| 52 Week Low | $136.91 | $31.58 |
| 52 Week High | $205.77 | $49.06 |
| Indicator | LDOS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 61.00 |
| Support Level | $154.52 | $35.32 |
| Resistance Level | $164.44 | $49.06 |
| Average True Range (ATR) | 3.68 | 0.90 |
| MACD | 0.67 | 0.06 |
| Stochastic Oscillator | 68.69 | 81.00 |
Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health management, both domestically and internationally. The customers of the company includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security & Digital, Health & Civil, Commercial & International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.